Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.
Sponsor: AstraZeneca
Listed as NCT00065117, this PHASE2 trial focuses on Colorectal Neoplasms and Metastases, Neoplasm and remains terminated or withdrawn. Sponsored by AstraZeneca, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Sep 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Chapel Hill, United States
- • Chicago, United States
- • Durham, United States
- • Los Angeles, United States
- • New Orleans, United States
- • New York, United States
- • Pittsburgh, United States
- • San Francisco, United States
- • St Louis, United States